Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Unternehmens-codeMEDP
Name des UnternehmensMedpace Holdings Inc
IPO-datumAug 11, 2016
Gegründet am2014
CEODr. August J. Troendle, M.D.
Anzahl der mitarbeiter5900
WertpapierartOrdinary Share
GeschäftsjahresendeAug 11
Addresse5375 Medpace Way
StadtCINCINNATI
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl45227-1543
Telefon15135799911
Websitehttps://investor.medpace.com/
Unternehmens-codeMEDP
IPO-datumAug 11, 2016
Gegründet am2014
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten